Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory R Pond

Showing results (181-190 of 255) with videos related to

Pageof 26
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|October 5, 2025
Changes in Frailty Categorization Over One Year among Real-World Patients With Multiple Myeloma: A Prospective Cohort Study (MFRAIL)Imran Haider, Darryl P Leong, Omar Shahid, et al.
Journal of Medical Internet Research|January 18, 2023
Web-Based Asynchronous Tool to Facilitate Communication Between Primary Care Providers and Cancer Specialists: Pragmatic Randomized Controlled TrialBojana Petrovic, Jim A Julian, Clare Liddy, et al.
NEJM Evidence|May 26, 2026
Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast CancerMark Clemons, Carol Stober, Gregory R Pond, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology GroupScott A Laurie, Desiree Hao, Natasha B Leighl, et al.
Cancer|February 21, 2008
Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiationArwa Abdelhameed, Gregory R Pond, Nicholas Mitsakakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumorsIgnacio Duran, Sebastien J Hotté, Holger Hirte, et al.
Clinical Genitourinary Cancer|June 27, 2013
Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial designGregory R Pond, Joaquim Bellmunt, Ronan Fougeray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2014
Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trialPamela J Goodwin, Roanne J Segal, Michael Vallis, et al.
International Journal of Radiation Oncology, Biology, Physics|November 3, 2004
Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional statusMala Bahl, Lillian L Siu, Gregory R Pond, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 25, 2022
Using machine learning to predict individual patient toxicities from cancer treatmentsKatherine Marie Cole, Mark Clemons, Sharon McGee, et al.
Pageof 26

Showing results (181-190 of 255) with videos related to

Sort By:
Pageof 26
Clinical Lymphoma, Myeloma & Leukemia|October 5, 2025
Changes in Frailty Categorization Over One Year among Real-World Patients With Multiple Myeloma: A Prospective Cohort Study (MFRAIL)Imran Haider, Darryl P Leong, Omar Shahid, et al.
Journal of Medical Internet Research|January 18, 2023
Web-Based Asynchronous Tool to Facilitate Communication Between Primary Care Providers and Cancer Specialists: Pragmatic Randomized Controlled TrialBojana Petrovic, Jim A Julian, Clare Liddy, et al.
NEJM Evidence|May 26, 2026
Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast CancerMark Clemons, Carol Stober, Gregory R Pond, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology GroupScott A Laurie, Desiree Hao, Natasha B Leighl, et al.
Cancer|February 21, 2008
Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiationArwa Abdelhameed, Gregory R Pond, Nicholas Mitsakakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumorsIgnacio Duran, Sebastien J Hotté, Holger Hirte, et al.
Clinical Genitourinary Cancer|June 27, 2013
Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial designGregory R Pond, Joaquim Bellmunt, Ronan Fougeray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2014
Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trialPamela J Goodwin, Roanne J Segal, Michael Vallis, et al.
International Journal of Radiation Oncology, Biology, Physics|November 3, 2004
Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional statusMala Bahl, Lillian L Siu, Gregory R Pond, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 25, 2022
Using machine learning to predict individual patient toxicities from cancer treatmentsKatherine Marie Cole, Mark Clemons, Sharon McGee, et al.
Pageof 26